Skip to main content
R
NeighborhoodReport

Montreal Road

Tucker, GA 30084
31
Homes
1
Streets

Address Directory

1 1459 Montreal Road E Unit 201 Tucker Unit

Owner: Emory University
Secretary - Metro Medical Supply INC. 13 businesses

Property Details

County
Dekalb_socrata County

Corporate Affiliations (7)

Metro Medical Supply INC. Merged
Secretary Louise Tashjian Corp Est. 1990 #K018234
Metro Infusion Services, INC. Merged
CEO Louise Tashjian Corp Est. 1991 #K114561
Metro Medical Supply INC. Merged
CEO Louise Tashjian Corp Est. 1990 #K018234
Metro Infusion Services, INC. Merged
Secretary Louise Tashjian Corp Est. 1991 #K114561
E.n.t. Consultants Of Atlanta, LTD. Dissolved
Secretary M M Corp Est. 1992 #K222829
E.n.t. Consultants Of Atlanta, LTD.
#1660847
Center For Cosmetic & Reconstructive Surgery, P.c. Admin. Dissolved
CEO Dr Movagharnia Corp Est. 1997 #K731754

Registered Businesses (13)

Emory Clinic
Health Services 13 emp $3,696,600/yr
Ge
Health Services
Lincoln Property Co
Real Estate 1 emp $131,320/yr
North Atlanta Medical Assoc PC
Health Services
Arthur J Green Do
Health Services
Northlake Eye & Cataract Ctr
Health Services 5 emp $1,494,500/yr
North Atlanta Medical Assoc
Health Services 3 emp $2,049,600/yr
Jimenez A Louis Dpm PC
Health Services
Beton Robert R Md
Health Services
Northeast Atlanta Assoc Gstrny
Health Services 8 emp $2,156,350/yr
Georgia
Health Services
David S Levenson Md
Health Services
Women's Cancer Alliance
Health Services 12 emp $2,827,350/yr

Business Directory (5)

Foot Ankle Leg Specialists Ga
Carla Barnett Executive Assistant Offices and Clinics of Podiatrists 5 to 9 $500,000 to $999,999
Thomas D Cain Dpm
Thomas Cain Owner Offices and Clinics of Podiatrists 1 to 4 Under $500,000
Career Transitions For Women
Richard Lieberman Executive Director
Heck Industries
Richard Lieberman vigilant
Ctr For Cos And Recon Surg
Dr Fara Movagharnia 866107

2 1459 Montreal Road E Unit 202 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

3 1459 Montreal Road E Unit 204 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

4 1459 Montreal Road E Unit 206 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

5 1459 Montreal Road E Unit 207 A Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

6 1459 Montreal Road E Unit 207 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

7 1459 Montreal Road E Unit 210 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

8 1459 Montreal Road E Unit 301 A Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

9 1459 Montreal Road E Unit 301 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

10 1459 Montreal Road E Unit 302 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

11 1459 Montreal Road E Unit 306 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

12 1459 Montreal Road E Unit 309 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

13 1459 Montreal Road E Unit 311 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

14 1459 Montreal Road E Unit 401 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

15 1459 Montreal Road E Unit 402 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

16 1459 Montreal Road E Unit 406 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

17 1459 Montreal Road E Unit 408 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

18 1459 Montreal Road E Unit 410 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

19 1459 Montreal Road E Unit 501 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

20 1459 Montreal Road E Unit 502 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

21 1459 Montreal Road E Unit 503 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

22 1459 Montreal Road E Unit 504 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

23 1459 Montreal Road E Unit 508 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

24 1459 Montreal Road E Unit 509 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

25 1459 Montreal Road E Unit 510 Tucker Unit

Owner: Emory University

Property Details

County
Dekalb_socrata County

26 1459 Montreal Road E Unit Ph Tucker Unit

Owner: Emory University INC

Property Details

County
Dekalb_socrata County

27 1573 Montreal Road W Rear Tucker

Owner: Sapp Mary Eberenz

Property Details

County
Dekalb_socrata County

28 1827 Montreal Road W Rear Tucker

Owner: Dosetareh Rayon & Dosetareh Isaac

Property Details

County
Dekalb_socrata County

29 1855 Montreal Road W Rear Tucker

Owner: Montreal Station LLC

Property Details

County
Dekalb_socrata County

30 1985 Montreal Road W Rear Tucker

Owner: Cip Lavista LLC

Property Details

County
Dekalb_socrata County

31 2015 Montreal Road W Rear Tucker

Owner: Kattisan Enterprises LLC
2 vehicles Secretary - Advanced Carpet & Air Duct Cle... 3 businesses

Property Details

County
Dekalb_socrata County

Corporate Affiliations (6)

Advanced Carpet & Air Duct Cleaning, INC. Admin. Dissolved
Secretary Nathan Ooziel Corp Est. 2006 #0607952
Advanced Carpet & Air Duct Cleaning, INC. Admin. Dissolved
CFO Nathan Ooziel Corp Est. 2006 #0607952
Comprehensive Comp Services, INC. Dissolved
CEO Lydia Hill-Oliver Corp Est. 1997 #K729814
Providers Of Professional Services, INC. Dissolved
Secretary Carolyn Chapman Corp Est. 2000 #0032379
Northeast Crown & Bridge, INC. Dissolved
CEO Matt Grant Corp Est. 2000 #0008774
Advanced Carpet & Air Duct Cleaning, INC. Admin. Dissolved
CEO Mikhael Sirota Corp Est. 2006 #0607952

Registered Businesses (3)

Ornela's Associates INC
Business Services 5 emp $488,800/yr
A Vincent Pope & Assoc INC
Engineering, Management, Accounting, Research and Related Industries 8 emp $924,120/yr
One Stop Personal Care INC
Health Services

Business Directory (1)

Pets Are People Too
Carl G Chapman Owner NULL

Vehicles (2)

Vehicles registered at this address
Owner Year Make Model
Leroy Courseault 2008 Chevrolet Tahoe
Leroy Courseault 2008 Chevrolet Tahoe

Source: County assessor records, public records & state business filings · Updated Feb 2026

Loading map...

Commercial Fleet Presence

FMCSA Motor Carrier Registry

Industrial
200
Carriers
1,425
Power Units
2,395
Drivers
7.1
Avg Fleet
For-Hire: 79
Private: 121
HazMat: 1
Passenger: 5
Largest Carriers in ZIP
STANDARD FORWARDING FREIGHT LLC
DOT #4323593 · Interstate
307 units
230 drivers
TUCCO
DOT #814987 · Intrastate
87 units
92 drivers
GEORGIA TRANSMISSION CORPORATION
DOT #894702 · Interstate
48 units
48 drivers
PHILLIPS LANDSCAPE INC
DOT #875992 · Intrastate
47 units
40 drivers
E-TRUCKING INC
DOT #2396892 · Interstate
39 units
22 drivers

200 registered motor carriers in this ZIP. operating 1425 power units. 1 handle hazardous materials. 79 for-hire carriers.

Explore Nearby in Tucker

Discover other neighborhoods in Tucker, GA and compare what they have to offer.

Federal Grants & Assistance

USAspending.gov grant awards to recipients in this neighborhood.

14 grant records found FY2024–2025
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
FY 2025 ILCL ~ STATE PLAN INDEPENDENT LIVING CENTERS
$685,100
FORMULA GRANT (A)
Sep 27, 2025
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
FY2024-2025 CENTERS FOR INDEPENDENT LIVING
$685,100
FORMULA GRANT (A)
Sep 24, 2024
Expression Therapeutics, INC.
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
CANCER TREATMENT RESEARCH
ALLOGENEIC CELL AND GENE THERAPY FOR NEUROENDOCRINE TUMORS - PROJECT SUMMARY/ABSRACT NEUROENDOCRINE TUMORS (NETS) ARE A TYPE OF RARE NEOPLASM THAT ORIGINATES FROM CELLS OF THE DIFFUSE NEUROENDOCRINE SYSTEM. IT IS ESTIMATED THAT MORE THAN 12,000 PEOPLE IN THE U.S. ARE DIAGNOSED WITH A NET EACH YEAR AND, IN TOTAL, APPROXIMATELY 171,000 PEOPLE IN THE U.S. ARE LIVING WITH NETS IN 2023. THE NUMBER OF INDIVIDUALS DIAGNOSED WITH THIS TYPE OF TUMOR HAS BEEN INCREASING CONSISTENTLY OVER THE PAST 30 YEARS, FROM 1.09 PER 100,000 PERSONS IN 1973 TO 6.98 PER 100,000 PERSONS BY 2012. THIS OBSERVED INCREASE IN NET INCIDENCE IS THOUGHT TO BE THE RESULT OF IMPROVEMENTS IN AWARENESS AND DIAGNOSTICS, INCLUDING BETTER IMAGING TESTS AND ENDOSCOPY. THE MAJORITY OF NETS, AND SPECIFICALLY WELL-DIFFERENTIATED AND FUNCTIONAL GEPNETS, EXPRESS THE SURFACE PROTEIN, SOMATOSTATIN RECEPTOR TYPE 2 (SSTR2), WHICH IS THE BASIS FOR BOTH DIAGNOSIS, IMAGING (INCLUDING MONITORING FOR PROGRESSION), AND SYMPTOMATIC THERAPY. TREATMENT OPTIONS FOR NEUROENDOCRINE TUMORS DEPEND ON FACTORS SUCH AS TUMORS SIZE, LOCATION, GRADE, AND MALIGNANT SPREAD. APPROACHES INCLUDE SURGICAL REMOVAL (IF POSSIBLE), TARGETED DRUG THERAPY, CHEMOTHERAPY, AND PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT). OTHER THAN RARE CASES LOCALIZED, SURGICALLY ACCESSIBLE DISEASE, THERE ARE NO CURATIVE THERAPIES FOR NETS. THE PRIMARY APPROVED DRUGS ARE SOMATOSTATIN ANALOGS (SSAS), SSA-BASED PRRT, AND A TRYPTOPHAN HYDROXYLASE INHIBITOR (BLOCKS SEROTONIN BIOSYNTHESIS; TELOTRISTAT ETHYL). WHILE THESE DRUGS CAN HELP ALLEVIATE SOME OF THE SYMPTOMS ASSOCIATED WITH THE SECRETION OF BIOACTIVE SUBSTANCES FROM FUNCTIONAL NETS, THEY DEMONSTRATE LITTLE TO NO EFFECT ON REDUCING TUMOR BURDEN OR GENERATING COMPLETE REMISSION. FURTHERMORE, PRRT AFFECTS ORGAN FUNCTION AND CAN LEAD TO SECONDARY MALIGNANCIES. THEREFORE, OTHER THAN THE LIMITED CASES WHERE COMPLETE SURGICAL RESECTION IS POSSIBLE, NO CURATIVE TREATMENT OPTIONS CURRENTLY EXIST. CELL AND GENE THERAPY (CGT)-BASED IMMUNO-ONCOLOGY (1-0) DRUGS ARE TRANSFORMING CANCER OUTCOME EXPECTATIONS. EXPRESSION THERAPEUTICS, INC. (ET) IS A FULLY INTEGRATED CGT COMPANY WITH AN ESTABLISHED EXECUTIVE TEAM THAT HAS DEMONSTRATED PROVEN SUCCESS IN PRECLINICAL EXECUTION, CLINICAL DEVELOPMENT, AND GMP MANUFACTURING OF TRANSFORMATIVE THERAPIES IN THE HEMOPHILIA AND ONCOLOGY SPACES. ET POSSESSES DIFFERENTIATED, PROPRIETARY PLATFORM TECHNOLOGIES INCLUDING THE LENTET GENE TRANSFER SYSTEM, EXPRESSION CASSETTE OPTIMIZATION (ECO), SECRETED T CELL ACTUATORS (STARS), AND ALLOGENEIC DONOR EXPANDED AND PROGRAMMED T (ADEPT) CELLS. EXPRESSION THERAPEUTICS HAS DEVELOPED CANDIDATE STAR EXPRESSED BY ADEPT CELLS THAT DISPLAYS POTENT CYTOTOXICITY AGAINST CANCER CELL LINES. THE OVERALL GOAL OF THE PROPOSED STUDIES IS TO ADVANCE A PROMISING LEAD ADEPT-STAR-NET CANDIDATE TOWARDS CLINICAL TESTING.
$400,000
PROJECT GRANT (B)
Dec 4, 2024
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
FY2022-2023 CENTERS FOR INDEPENDENT LIVING - FY2022-2023 CENTERS FOR INDEPENDENT LIVING
$614,194
FORMULA GRANT (A)
Apr 24, 2025
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
FY22 PUBLIC HEALTH WORKFORCE FUNDING FOR PART C CILS
$130,263
FORMULA GRANT (A)
May 1, 2025
Natglycan LLC
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
BIOMEDICAL RESEARCH AND RESEARCH TRAINING
NATURAL GLYCANS FOR FUNCTIONAL GLYCOMICS - NATURAL GLYCANS FOR FUNCTIONAL GLYCOMICS PROJECT SUMMARY/ ABSTRACT DURING THE FIRST DECADE OF THE 21ST CENTURY, NIH MADE SIGNIFICANT INVESTMENTS IN GLYCOMICS. THE CONSORTIUM FOR FUNCTIONAL GLYCOMICS (SUPPORTED BY NIGMS 2001-2012) LED A MAJOR INTERNATIONAL EFFORT USING A MICROARRAY OF 611 DEFINED GLYCANS TO IDENTIFY THE PROTEIN-GLYCAN INTERACTIONS ASSOCIATED WITH NORMAL PHYSIOLOGY AND DISEASE (HTTP://WWW.FUNCTIONALGLYCOMICS.ORG/CFGPARADIGMS/INDEX.PHP/WELCOME_TO_THE_CFG_PARADIGM_PAGES). THIS 611 GLYCAN LIBRARY TRANSFORMED STUDIES ON PROTEIN-GLYCAN INTERACTIONS AND REVEALED THE IMPORTANCE OF DEFINING THE HUMAN GLYCOME, ESTIMATED TO BE IN THE RANGE OF 10,000 DETERMINANTS. A MICROARRAY COMPRISED OF ALL POSSIBLE GLYCANS WOULD ALLOW US TO DETECT AND DEFINE ALL PHYSIOLOGICALLY RELEVANT GLYCAN BINDING PROTEINS (GBP), BUT THE CFG LIBRARY IS NOW ONLY 575 GLYCANS MAKING THE PRODUCTION OF LARGE QUANTITIES OF PURE, DEFINED GLYCANS FOR FUNCTIONAL STUDIES CRITICAL FOR ADVANCING GLYCOMICS; E.G, MGS OF PURE HUMAN MILK OLIGOSACCHARIDES (HMO), AVAILABLE SINCE THE 1950’S SUPPORTED RESEARCH THAT LED TO OUR UNDERSTANDING OF THE BENEFITS OF HMO IN BREASFED INFANTS, RESULTING IN INFANT FORMULA MANUFACTURERS INTRODUCING HMO INTO THEIR PRODUCTS IN 2014, BASED ON CLINICAL TRIALS SUPPORTING THEIR EFFICACY. MAMMALIAN GLYCANS,ON THE OTHER HAND, EXPRESSED ON THE SURFACES OF ALL CELLS, ARE GENERALLY AVAILABLE ONLY IN MINUTE QUANTITIES; MAKING THEM AS AVAILABLE AS HMO TO THE RESEARCH COMMUNITY WOULD RAPIDLY ADVANCE UNDERSTANDING OF THEIR FUNCTIONS IN ANIMAL CELLS. THIS IS NOW POSSIBLE USING OUR PROPRIETARY TECHNOLOGY, OXIDATIVE RELEASE OF NATURAL GLYCANS (ORNG), WHICH CHEMICALLY RELEASES GLYCANS FROM GLYCOCONJUGATES OF ANY NATURAL MATERIAL USING HOUSEHOLD BLEACH. NATGLYCAN, LLC (NGC) WAS ESTABLISHED TO PROVIDE BIOLOGICALLY RELEVANT NATURAL GLYCANS RELIABLY, ECONOMICALLY, AND IN LARGE QUANTITIES. IN PHASE I WE DEMONSTRATED THE FEASIBILITY OF PRODUCING HIGH MANNOSE N-GLYCANS IN MG QUANTITIES FOR SALE TO THE GLYCOSCIENCE COMMUNITY FOR THE FIRST TIME. WE BELIEVE THE ECONOMY OF SCALE WILL SUPPORT REASONABLE PRICES. SIGMA-ALDRICH SELLS 20ΜG OF MAN9GLCNAC2 FOR $688, WHILE NGC IS SELLING 5 MG OF MAN9GLCNAC2-AEAB FOR $750. IN PHASE II OF THIS PROJECT WE WILL COMPLETE A MANUFACTURING FACILITY TO PRODUCE 100’S OF MG (PURITY >95%) OF ALL HIGH MANNOSE N- GLYCANS AND DERIVATIVES THAT WILL BE USEFUL TO THE GLYCOBIOLOGY COMMUNITY. IN ADDITION, WE PLAN TO LAUNCH HIGHLY PURIFIED N-GLYCANS REPRESENTING ALL OF THE STRUCTURES EXPRESSED ON HUMAN AND RECOMBINANT IGG FOR USE AS QC STANDARDS IN MAB MANUFACTURING; CURRENTLY AN UNMET NEED IN THE PHARMACEUTICAL INDUSTRY. SINCE ORNG RELEASES ALL CLASSES OF GLYCANS SIMULTANEOUSLY FROM NATURAL PRODUCTS, WE WILL RAPIDLY EXPAND OUR PRODUCT OFFERINGS. WE WILL PURIFY THE MAJOR O-GLYCANS THAT ARE IN GREAT DEMAND, BUT NOT CURRENTLY AVAILABLE AT REASONABLE COST. WE ANTICIPATE THAT BY THE END OF PHASE II, WE WILL BE OFFERING HUNDREDS OF N-GLYCANS AND O-GLYCANS (PURITY >95%) AND USEFUL DERIVATIVES IN MULTI-MILIGRAM AMOUNTS. BASED ON SIGNIFICANT SALES AND ORDERS AFTER OUR INITIAL PRODUCT CATALOG LAUNCH, WE ANTICIPATE BEING ABLE TO SUPPORT OUR GLYCAN MANUFACTURING COSTS AND INCREASE PROFIT MARGINS AS WE INCREASE MANUFACTURING SCALE IN THE FUTURE.
$1,870,936
PROJECT GRANT (B)
Jun 6, 2024
Natglycan LLC
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
ORAL DISEASES AND DISORDERS RESEARCH
A HUMAN SALIVARY GLYCOME DISCOVERY PLATFORM FOR INTERROGATING GLYCAN FUNCTION IN ORAL INNATE IMMUNITY - PROJECT SUMMARY THE ORAL CAVITY IS THE FIRST CRITICAL INTERFACE BETWEEN POTENTIALLY HARMFUL SUBSTANCES OR PATHOGENS IN THE HOST ENVIRONMENT, AND EVOLUTION OF THE ADAPTIVE AND INNATE IMMUNE DEFENSE MECHANISMS TO INACTIVATE OR ELIMINATE PATHOGENIC MICROBES HAS TO A GREAT EXTENT USED PROTEIN-GLYCAN INTERACTION. THE GLYCAN COMPONENTS OF SALIVA HAVE BEEN SHOWN TO PLAY IMPORTANT ROLES IN BIOLOGICAL AND IMMUNOLOGICAL ASPECTS OF ORAL HOST-MICROBE, MICROBE- HOST, AND MICROBE-MICROBE INTERACTIONS, AND WE HAVE SHOWN THAT GLYCANS ATTACHED SALIVARY GLYCOPROTEINS CAN ACT AS A FIRST LINE OF HOST DEFENSE IN THE HUMAN MOUTH AND THAT GLYCAN RECOGNITION CONTRIBUTES TO BOTH COLONIZATION AND CLEARANCE OF ORAL MICROBES. A REVOLUTIONARY INNOVATION IN STUDIES OF PROTEIN-GLYCAN INTERACTIONS WAS THE GLYCAN MICROARRAY, WHICH PERMITTED THE IDENTIFICATION GLYCAN LIGANDS FOR BIOLOGICALLY RELEVANT GLYCAN BINDING PROTEINS (GBP) BY THEIR SIMULTANEOUS INTERROGATION WITH HUNDREDS OF GLYCAN STRUCTURES PRINTED ON A MICROSCOPE SLIDE. COMPARISONS OF THE STRUCTURES OF BOUND AND NON-BOUND GLYCANS REVEAL THE GLYCAN SPECIFICITY OF GBP, AND THIS INFORMATION IS USED IN FURTHER BIOLOGICAL STUDIES TO UNDERSTAND THE BIOLOGICAL FUNCTION OF GBP. IN THIS PROJECT WE WILL GENERATE A GLYCAN MICROARRAY COMPOSED OF GLYCANS THAT REPRESENT THE SALIVARY GLYCOME, I.E. THE ENTIRETY OF GLYCANS IN SALIVA. THIS WILL BE ACCOMPLISHED BY FIRST PRODUCING A LIBRARY OF PURIFIED, NATURALLY OCCURRING N- AND O-LINKED GLYCANS RELEASED FROM 10 LITERS OF POOLED HUMAN SALIVA BY AN INNOVATIVE PROCESS FOR THE OXIDATIVE RELEASE OF NATURAL GLYCANS (ORNG) USING SIMPLE HOUSEHOLD BLEACH. THE LIBRARY OF GLYCANS WILL BE PRINTED AS A GLYCAN MICROARRAY AND INTERROGATED WITH ORAL STREPTOCOCCAL GLYCAN-BINDING ADHESINS TO IDENTIFY THEIR CORRESPONDING NATURAL HIGH-AFFINITY GLYCAN LIGANDS. WE WILL USE OUR RECENTLY ESTABLISHED TOOLBOX OF STREPTOCOCCAL SERINE-RICH-REPEAT PROTEIN ADHESINS THAT EACH CONTAIN SIALIC-ACID-BINDING SIGLEC-LIKE DOMAINS OF DIFFERING SPECIFICITY FOR SUBTYPES OF SIALIC ACIDS IN THE WIDER CONTEXT OF THEIR UNDERLYING SUBTERMINAL GLYCANS. FOR SOME OF THESE LECTINS, THE NATURAL GLYCAN LIGANDS WERE NOT IDENTIFIED USING CURRENTLY AVAILABLE ARRAYS, PRESUMABLY DUE TO THE ABSENCE OF THEIR CORRESPONDING NATURAL GLYCAN LIGANDS PRESENTED IN THE ASSAYS TO DATE. SINCE THESE ARE LECTINS EXPRESSED BY ORAL MICROBES, WE ANTICIPATE THAT THERE IS A HIGH PROBABILITY THAT THEIR NATURAL GLYCAN LIGANDS WILL BE PRESENT IN THE GLYCOME OF HUMAN SALIVA, THE NATURAL BIOLOGICAL FLUID IN WHICH THESE MICROORGANISMS THRIVE. THIS PHASE I PROJECT SHOULD PROVIDE AN EXAMPLE OF HOW A COMPLETE GLYCOME CAN BE USED AS A DISCOVERY PLATFORM FOR IDENTIFYING A NOVEL PROTEIN-GLYCAN INTERACTION. ONCE THE DETAILS OF THE STRUCTURE OF THE GLYCAN LIGAND ARE DEFINED, THE INFORMATION WILL BECOME INTELLECTUAL PROPERTY THAT WILL LEAD TO STRATEGIES TO THERAPEUTICALLY INTERFERE WITH MICROBIAL COLONIZATION OR PATHOGEN INFECTION IN THE MOUTH AND BEYOND. THIS PLATFORM FOR UNDERSTANDING THE INTERACTIONS OF ORAL MICROORGANISMS AND EXTRAORAL SYSTEMIC PATHOGENS WITH THE HUMAN MAY ULTIMATELY LEAD TO THE DEVELOPMENT OF AN IMPROVED ARTIFICIAL SALIVA, MORE CLOSELY MIMICKING THE GLYCAN LANDSCAPE OF NATURAL HUMAN SALIVA, AS ADDITION OF HUMAN MILK OLIGOSACCHARIDES HAS LAID THE GROUNDWORK FOR IMPROVEMENT OF INFANT FORMULA.
$314,971
PROJECT GRANT (B)
Sep 29, 2025
Natglycan LLC
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
BIOMEDICAL RESEARCH AND RESEARCH TRAINING
NATURAL GLYCANS FOR FUNCTIONAL GLYCOMICS - NATURAL GLYCANS FOR FUNCTIONAL GLYCOMICS PROJECT SUMMARY/ ABSTRACT DURING THE FIRST DECADE OF THE 21ST CENTURY, NIH MADE SIGNIFICANT INVESTMENTS IN GLYCOMICS. THE CONSORTIUM FOR FUNCTIONAL GLYCOMICS (SUPPORTED BY NIGMS 2001-2012) LED A MAJOR INTERNATIONAL EFFORT USING A MICROARRAY OF 611 DEFINED GLYCANS TO IDENTIFY THE PROTEIN-GLYCAN INTERACTIONS ASSOCIATED WITH NORMAL PHYSIOLOGY AND DISEASE (HTTP://WWW.FUNCTIONALGLYCOMICS.ORG/CFGPARADIGMS/INDEX.PHP/WELCOME_TO_THE_CFG_PARADIGM_PAGES). THIS 611 GLYCAN LIBRARY TRANSFORMED STUDIES ON PROTEIN-GLYCAN INTERACTIONS AND REVEALED THE IMPORTANCE OF DEFINING THE HUMAN GLYCOME, ESTIMATED TO BE IN THE RANGE OF 10,000 DETERMINANTS. A MICROARRAY COMPRISED OF ALL POSSIBLE GLYCANS WOULD ALLOW US TO DETECT AND DEFINE ALL PHYSIOLOGICALLY RELEVANT GLYCAN BINDING PROTEINS (GBP), BUT THE CFG LIBRARY IS NOW ONLY 575 GLYCANS MAKING THE PRODUCTION OF LARGE QUANTITIES OF PURE, DEFINED GLYCANS FOR FUNCTIONAL STUDIES CRITICAL FOR ADVANCING GLYCOMICS; E.G, MGS OF PURE HUMAN MILK OLIGOSACCHARIDES (HMO), AVAILABLE SINCE THE 1950’S SUPPORTED RESEARCH THAT LED TO OUR UNDERSTANDING OF THE BENEFITS OF HMO IN BREASFED INFANTS, RESULTING IN INFANT FORMULA MANUFACTURERS INTRODUCING HMO INTO THEIR PRODUCTS IN 2014, BASED ON CLINICAL TRIALS SUPPORTING THEIR EFFICACY. MAMMALIAN GLYCANS,ON THE OTHER HAND, EXPRESSED ON THE SURFACES OF ALL CELLS, ARE GENERALLY AVAILABLE ONLY IN MINUTE QUANTITIES; MAKING THEM AS AVAILABLE AS HMO TO THE RESEARCH COMMUNITY WOULD RAPIDLY ADVANCE UNDERSTANDING OF THEIR FUNCTIONS IN ANIMAL CELLS. THIS IS NOW POSSIBLE USING OUR PROPRIETARY TECHNOLOGY, OXIDATIVE RELEASE OF NATURAL GLYCANS (ORNG), WHICH CHEMICALLY RELEASES GLYCANS FROM GLYCOCONJUGATES OF ANY NATURAL MATERIAL USING HOUSEHOLD BLEACH. NATGLYCAN, LLC (NGC) WAS ESTABLISHED TO PROVIDE BIOLOGICALLY RELEVANT NATURAL GLYCANS RELIABLY, ECONOMICALLY, AND IN LARGE QUANTITIES. IN PHASE I WE DEMONSTRATED THE FEASIBILITY OF PRODUCING HIGH MANNOSE N-GLYCANS IN MG QUANTITIES FOR SALE TO THE GLYCOSCIENCE COMMUNITY FOR THE FIRST TIME. WE BELIEVE THE ECONOMY OF SCALE WILL SUPPORT REASONABLE PRICES. SIGMA-ALDRICH SELLS 20ΜG OF MAN9GLCNAC2 FOR $688, WHILE NGC IS SELLING 5 MG OF MAN9GLCNAC2-AEAB FOR $750. IN PHASE II OF THIS PROJECT WE WILL COMPLETE A MANUFACTURING FACILITY TO PRODUCE 100’S OF MG (PURITY >95%) OF ALL HIGH MANNOSE N- GLYCANS AND DERIVATIVES THAT WILL BE USEFUL TO THE GLYCOBIOLOGY COMMUNITY. IN ADDITION, WE PLAN TO LAUNCH HIGHLY PURIFIED N-GLYCANS REPRESENTING ALL OF THE STRUCTURES EXPRESSED ON HUMAN AND RECOMBINANT IGG FOR USE AS QC STANDARDS IN MAB MANUFACTURING; CURRENTLY AN UNMET NEED IN THE PHARMACEUTICAL INDUSTRY. SINCE ORNG RELEASES ALL CLASSES OF GLYCANS SIMULTANEOUSLY FROM NATURAL PRODUCTS, WE WILL RAPIDLY EXPAND OUR PRODUCT OFFERINGS. WE WILL PURIFY THE MAJOR O-GLYCANS THAT ARE IN GREAT DEMAND, BUT NOT CURRENTLY AVAILABLE AT REASONABLE COST. WE ANTICIPATE THAT BY THE END OF PHASE II, WE WILL BE OFFERING HUNDREDS OF N-GLYCANS AND O-GLYCANS (PURITY >95%) AND USEFUL DERIVATIVES IN MULTI-MILIGRAM AMOUNTS. BASED ON SIGNIFICANT SALES AND ORDERS AFTER OUR INITIAL PRODUCT CATALOG LAUNCH, WE ANTICIPATE BEING ABLE TO SUPPORT OUR GLYCAN MANUFACTURING COSTS AND INCREASE PROFIT MARGINS AS WE INCREASE MANUFACTURING SCALE IN THE FUTURE.
$1,870,936
PROJECT GRANT (B)
Apr 14, 2025
Novab, INC
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
CANCER TREATMENT RESEARCH
NOVEL TARGETED CAR-T MULTIPLE MYELOMA THERAPY - PROJECT SUMMARY MULTIPLE MYELOMA (MM), A MALIGNANCY OF PLASMA CELLS (PCS), IS RESPONSIBLE FOR OVER 12,500 DEATHS IN THE US AND OVER 117,000 DEATHS WORLDWIDE ANNUALLY. OVER 91,000 INDIVIDUALS IN THE US AND OVER 300,000 WORLDWIDE CURRENTLY LIVE WITH MM. IN SPITE OF MAJOR THERAPEUTIC ADVANCES IN THE PAST TWO DECADES, MM REMAINS INCURABLE AND MOST MM PATIENTS SUCCUMB TO THE UNDERLYING MALIGNANCY. RECENT THERAPIES REDIRECTING T CELLS VIA CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-TS) OR BISPECIFIC ANTIBODIES THAT TARGET B CELL MATURATION ANTIGEN (BCMA) HAVE SIGNIFICANTLY IMPROVED SURVIVAL OF PATIENTS WITH DISEASE REFRACTORY TO PRIOR THERAPIES. HOWEVER, NEARLY ALL MM PATIENTS EXPERIENCE DISEASE PROGRESSION AND BECOME REFRACTORY TO THESE BCMA-TARGETED T CELL THERAPIES. THERE IS THEREFORE AN URGENT UNMET NEED TO DEVELOP NEW TARGETS FOR THESE POTENT T CELL-DIRECTED MM THERAPIES. THIS PHASE 1 SBIR APPLICATION ADDRESSES THAT NEED WITH A NOVEL MONOCLONAL ANTIBODY (MAB) DESIGNATED MM3. MM3 BELONGS TO A NEW CLASS OF ANTIBODIES, VARIABLE LYMPHOCYTE RECEPTOR B (VLRB) ANTIBODIES PRODUCED BY THE B CELLS OF JAWLESS VERTEBRATES, LAMPREY AND HAGFISH, AND SPECIFICALLY BINDS TO A DISTINCTIVE FORM OF A WELL-VALIDATED MM THERAPEUTIC TARGET, MULTIMERIC FORMS OF THE CD38 CELL SURFACE PROTEIN, WITH NO DETECTABLE BINDING TO CD38 MONOMERS. CD38 MULTIMERS ARE UNIQUELY EXPRESSED BY PCS AND MM TUMORS, WHEREAS CD38 MONOMERS ARE EXPRESSED BY NUMEROUS OTHER NORMAL CELL TYPES, INCLUDING NK AND T CELL IMMUNE EFFECTORS. CAR-T CELLS THAT UTILIZE MM3 AS TARGET RECOGNITION DOMAIN THEREFORE AVOID POTENTIAL “ON-TARGET/OFF-TUMOR” TOXICITY ASSOCIATED WITH BINDING TO MONOMERIC CD38, “FRATRICIDE” AMONG CAR-T CELLS THAT EXPRESS BOTH MONOMERIC CD38 AND CAR ANTIGEN BINDING DOMAINS THAT BIND MONOMERIC CD38, AND DEPLETION OF NK AND T CELL IMMUNE EFFECTORS. MULTIMERIC CD38 IS HIGHLY EXPRESSED BY THE TUMOR CELLS OF RELAPSED-REFRACTORY MM (RRMM) PATIENTS REFRACTORY TO PROTEASOME AND/OR IMMUNOMODULATOR DRUGS. ALTHOUGH DOWNREGULATION OF CD38 EXPRESSION IS ONE OF SEVERAL MECHANISMS OF RESISTANCE TO ANTI-CD38 MAB THERAPY, E.G., DARATUMUMAB, HIGH LEVELS OF CD38 AND MULTIMERIC CD38 EXPRESSION RETURN WITHIN 3 TO 6 MONTHS OF ANTI-CD38 MAB THERAPY DISCONTINUATION, AND MM TUMOR CELLS OF OVER 87% OF RRMM PATIENTS EXPRESS HIGH LEVELS OF CD38 MULTIMERS DETECTED WITH MM3. MM3 HUMAN CAR-T CELLS HAVE BEEN PRODUCED AND SHOWN WITH IN VITRO ASSAYS TO DIRECT CAR-T KILLING ONLY TO CELLS THAT EXPRESS MULTIMERIC CD38. THIS APPLICATION WILL EXTEND THOSE RESULTS BY: (1) PRODUCING MM3 CAR-T CELLS WITH T CELL PREPARATIONS DERIVED FROM HEALTHY HUMAN VOLUNTEERS AND FROM PATIENTS RELAPSED FOLLOWING ANTI-BCMA CAR-T THERAPY AND EVALUATING IN VITRO TARGET-SPECIFIC ACTIVATION AND CYTOTOXICITY AGAINST A MM CELL LINE AND AUTOLOGOUS MM TUMOR CELLS FROM ANTI-BCMA CAR-T RELAPSED MM PATIENTS, AND (2) EVALUATING THE IN VIVO ANTI-TUMOR EFFICACY OF MM3 CAR-T CELLS WITH MISTRG6 “HUMANIZED” MICE ENGRAFTED WITH A HUMAN MM TUMOR CELL LINE. THESE PHASE 1 STUDIES WILL BE FOLLOWED BY PHASE 2 IN VIVO EVALUATIONS OF MM3 CAR-TS PRODUCED WITH RRMM PATIENT T CELLS AGAINST TUMORS FROM THOSE SAME PATIENTS IN THE MISTRG6 MODEL AND BY GMP PRODUCTION OF MM3 CAR LENTIVIRUS AND MM3 CAR-T CELLS, AND IND-ENABLING PHARMACOLOGY/TOXICOLOGY STUDIES TO SUPPORT FIRST IN HUMAN CLINICAL TRIALS OF THIS NEW CAR-T THERAPY FOR MM PATIENTS THAT HAVE FAILED ALL OTHER THERAPIES.
$301,956
PROJECT GRANT (B)
Mar 11, 2025
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
2020 ILC3 - CARES
$575,051
FORMULA GRANT (A)
Oct 16, 2023
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
FY21 PART C CILS ACCESS TO COVID 19 VACCINES
$17,921
FORMULA GRANT (A)
Dec 1, 2023
Disability Action Center Of Georgia, INC.
1901 Montreal Rd
Department of Health and Human Services / Administration for Community Living
ACL CENTERS FOR INDEPENDENT LIVING
2021 CILS
$595,834
FORMULA GRANT (A)
Jun 26, 2024
Natglycan LLC
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
ORAL DISEASES AND DISORDERS RESEARCH
A HUMAN SALIVARY GLYCOME DISCOVERY PLATFORM FOR INTERROGATING GLYCAN FUNCTION IN ORAL INNATE IMMUNITY - PROJECT SUMMARY THE ORAL CAVITY IS THE FIRST CRITICAL INTERFACE BETWEEN POTENTIALLY HARMFUL SUBSTANCES OR PATHOGENS IN THE HOST ENVIRONMENT, AND EVOLUTION OF THE ADAPTIVE AND INNATE IMMUNE DEFENSE MECHANISMS TO INACTIVATE OR ELIMINATE PATHOGENIC MICROBES HAS TO A GREAT EXTENT USED PROTEIN-GLYCAN INTERACTION. THE GLYCAN COMPONENTS OF SALIVA HAVE BEEN SHOWN TO PLAY IMPORTANT ROLES IN BIOLOGICAL AND IMMUNOLOGICAL ASPECTS OF ORAL HOST-MICROBE, MICROBE- HOST, AND MICROBE-MICROBE INTERACTIONS, AND WE HAVE SHOWN THAT GLYCANS ATTACHED SALIVARY GLYCOPROTEINS CAN ACT AS A FIRST LINE OF HOST DEFENSE IN THE HUMAN MOUTH AND THAT GLYCAN RECOGNITION CONTRIBUTES TO BOTH COLONIZATION AND CLEARANCE OF ORAL MICROBES. A REVOLUTIONARY INNOVATION IN STUDIES OF PROTEIN-GLYCAN INTERACTIONS WAS THE GLYCAN MICROARRAY, WHICH PERMITTED THE IDENTIFICATION GLYCAN LIGANDS FOR BIOLOGICALLY RELEVANT GLYCAN BINDING PROTEINS (GBP) BY THEIR SIMULTANEOUS INTERROGATION WITH HUNDREDS OF GLYCAN STRUCTURES PRINTED ON A MICROSCOPE SLIDE. COMPARISONS OF THE STRUCTURES OF BOUND AND NON-BOUND GLYCANS REVEAL THE GLYCAN SPECIFICITY OF GBP, AND THIS INFORMATION IS USED IN FURTHER BIOLOGICAL STUDIES TO UNDERSTAND THE BIOLOGICAL FUNCTION OF GBP. IN THIS PROJECT WE WILL GENERATE A GLYCAN MICROARRAY COMPOSED OF GLYCANS THAT REPRESENT THE SALIVARY GLYCOME, I.E. THE ENTIRETY OF GLYCANS IN SALIVA. THIS WILL BE ACCOMPLISHED BY FIRST PRODUCING A LIBRARY OF PURIFIED, NATURALLY OCCURRING N- AND O-LINKED GLYCANS RELEASED FROM 10 LITERS OF POOLED HUMAN SALIVA BY AN INNOVATIVE PROCESS FOR THE OXIDATIVE RELEASE OF NATURAL GLYCANS (ORNG) USING SIMPLE HOUSEHOLD BLEACH. THE LIBRARY OF GLYCANS WILL BE PRINTED AS A GLYCAN MICROARRAY AND INTERROGATED WITH ORAL STREPTOCOCCAL GLYCAN-BINDING ADHESINS TO IDENTIFY THEIR CORRESPONDING NATURAL HIGH-AFFINITY GLYCAN LIGANDS. WE WILL USE OUR RECENTLY ESTABLISHED TOOLBOX OF STREPTOCOCCAL SERINE-RICH-REPEAT PROTEIN ADHESINS THAT EACH CONTAIN SIALIC-ACID-BINDING SIGLEC-LIKE DOMAINS OF DIFFERING SPECIFICITY FOR SUBTYPES OF SIALIC ACIDS IN THE WIDER CONTEXT OF THEIR UNDERLYING SUBTERMINAL GLYCANS. FOR SOME OF THESE LECTINS, THE NATURAL GLYCAN LIGANDS WERE NOT IDENTIFIED USING CURRENTLY AVAILABLE ARRAYS, PRESUMABLY DUE TO THE ABSENCE OF THEIR CORRESPONDING NATURAL GLYCAN LIGANDS PRESENTED IN THE ASSAYS TO DATE. SINCE THESE ARE LECTINS EXPRESSED BY ORAL MICROBES, WE ANTICIPATE THAT THERE IS A HIGH PROBABILITY THAT THEIR NATURAL GLYCAN LIGANDS WILL BE PRESENT IN THE GLYCOME OF HUMAN SALIVA, THE NATURAL BIOLOGICAL FLUID IN WHICH THESE MICROORGANISMS THRIVE. THIS PHASE I PROJECT SHOULD PROVIDE AN EXAMPLE OF HOW A COMPLETE GLYCOME CAN BE USED AS A DISCOVERY PLATFORM FOR IDENTIFYING A NOVEL PROTEIN-GLYCAN INTERACTION. ONCE THE DETAILS OF THE STRUCTURE OF THE GLYCAN LIGAND ARE DEFINED, THE INFORMATION WILL BECOME INTELLECTUAL PROPERTY THAT WILL LEAD TO STRATEGIES TO THERAPEUTICALLY INTERFERE WITH MICROBIAL COLONIZATION OR PATHOGEN INFECTION IN THE MOUTH AND BEYOND. THIS PLATFORM FOR UNDERSTANDING THE INTERACTIONS OF ORAL MICROORGANISMS AND EXTRAORAL SYSTEMIC PATHOGENS WITH THE HUMAN MAY ULTIMATELY LEAD TO THE DEVELOPMENT OF AN IMPROVED ARTIFICIAL SALIVA, MORE CLOSELY MIMICKING THE GLYCAN LANDSCAPE OF NATURAL HUMAN SALIVA, AS ADDITION OF HUMAN MILK OLIGOSACCHARIDES HAS LAID THE GROUNDWORK FOR IMPROVEMENT OF INFANT FORMULA.
$314,971
PROJECT GRANT (B)
Jul 26, 2024
Expression Therapeutics, INC.
1860 Montreal Rd
Department of Health and Human Services / National Institutes of Health
CANCER TREATMENT RESEARCH
ADEPT-STAR THERAPY FOR HIGH RISK NEUROBLASTOMA - PROJECT SUMMARY CANCER REMAINS A PRIMARY HEALTH CONCERN DESPITE SIGNIFICANT ADVANCEMENTS IN TREATMENT. IN THE PAST DECADE, CELL AND GENE (C&G) THERAPIES ALONG WITH IMMUNO-ONCOLOGY (I-O) THERAPIES HAVE TRANSFORMED TREATMENT EXPECTATIONS BY EXTENDING CANCER FREE SURVIVAL AND COMPLETE REMISSIONS. DESPITE THESE REMARKABLE SUCCESSES, THEY ARE LIMITED TO A SUBSET OF CANCERS AND MANY SIGNIFICANT CHALLENGES REMAIN FOR BROADER APPLICATION AND TO UNLOCK THE PERCEIVED MEDICAL AND COMMERCIAL POTENTIAL. EXPRESSION THERAPEUTICS, INC. (ET) IS A FULLY INTEGRATED C&G THERAPY COMPANY ADDRESSING THESE UNMET CLINICAL NEEDS BY USING PROPRIETARY AND COMPLEMENTARY PLATFORM TECHNOLOGIES THAT OPTIMIZE THERAPEUTIC TRANSGENE EXPRESSION AND GENE DELIVERY FOR THE DEVELOPMENT OF OFF-THE-SHELF ALLOGENEIC- BASED GENE THERAPIES. THESE TECHNOLOGIES ADDRESS MAJOR CHALLENGES BEING ENCOUNTERED IN C&G I-O: IDENTIFICATION OF SAFE AND EFFECTIVE TUMOR TARGETS, MAXIMIZING TREATMENT DURABILITY AND EFFICACY AND REDUCING THE COST OF GOODS. RESULTS OF PRELIMINARY IN VITRO AND IN VIVO STUDIES SUPPORT FEASIBILITY OF THE PROPOSED APPLICATION AND THE SUCCESSFUL DEVELOPMENT OF THIS ROBUST PLATFORM FOR THE TREATMENT OF PEDIATRIC NEUROBLASTOMAS AND OTHER FORMS OF NEUROENDOCRINE TUMORS (NETS) PROPOSED IN THIS APPLICATION.
$388,188
PROJECT GRANT (B)
Jan 30, 2025

Schools & Education

Part of DeKalb County School District. 3 nearby schools serving this area.

E
Elementary

Livsey Elementary School

Score 50/100
Enrollment 360
Distance 0.2 mi
M
Middle

Tucker Middle School

Score 31/100
Enrollment 1,221
Distance 0.1 mi
H
High School

Tucker High School

Enrollment 1,805
Distance 0.0 mi

Source: National Center for Education Statistics (NCES) · Updated Feb 2026

At a Glance

Best School
50/100
3 nearby schools
Stability
Stable
55/100
31 homes · 1 street

Montreal Road exhibits moderate stability with a mix of long-term and newer residents.

Continue Your Research

Frequently Asked Questions

What school district is Montreal Road in?
Montreal Road is served by DeKalb County School District. The highest-rated nearby school scores 50/100.
How many homes are in Montreal Road?
Montreal Road in Tucker, GA has 31 homes across 1 street.
Is Montreal Road good for families?
Montreal Road is served by DeKalb County School District (top school score: 50/100). The neighborhood has 31 homes across 1 street, providing a close-knit community for families.
What elementary school serves Montreal Road?
The nearest elementary school is Livsey Elementary School, located 0.2 miles away. It has 360 students enrolled.
What high school serves Montreal Road?
The nearest high school is Tucker High School, located 0.0 miles away.
Is Montreal Road a stable neighborhood?
Montreal Road has a stability score of 55/100, classified as "Stable." This indicates moderate stability with some residential turnover.

Data Sources & Methodology

5 verified data sources power this report

Property tax & valuation records

Federal education statistics

Healthcare facility & outcome data

Transportation & hazard data

5-year community survey estimates

Last updated:

View full methodology

Get Neighborhood Updates

Stay informed about changes in Montreal Road.